Cas no 2259-96-3 (Cyclothiazide)

Cyclothiazide is a thiazide-like diuretic and antihypertensive agent, primarily used to manage edema and hypertension. Its mechanism of action involves inhibiting the Na+-Cl- symporter in the distal convoluted tubule of the kidney, promoting sodium and water excretion while retaining potassium. Cyclothiazide exhibits a longer duration of action compared to conventional thiazides, enhancing patient compliance with less frequent dosing. It is also noted for its additional carbonic anhydrase inhibitory activity, which may contribute to its efficacy in certain clinical scenarios. The compound is typically administered orally and is valued for its predictable pharmacokinetics and well-established safety profile in appropriate patient populations.
Cyclothiazide structure
Cyclothiazide structure
Product Name:Cyclothiazide
CAS No:2259-96-3
MF:C14H16ClN3O4S2
MW:389.877539634705
CID:259069
PubChem ID:2910
Update Time:2025-11-02

Cyclothiazide Chemical and Physical Properties

Names and Identifiers

    • 2H-1,2,4-Benzothiadiazine-7-sulfonamide,3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide
    • Cyclothiazide
    • Cyclothiazide (mixture of isomers)
    • 2H-1,2,4-Benzothiadiazine-7-sulfonamide,3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, ...
    • 3-(5-bicyclo[2.2.1]hept-2-enyl)-6-chloro-1,1-dioxo-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide
    • 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2-4-benzothiadiazine-7-sulfonamide 1,1-dioxide
    • 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2-4-benzothiadiazine-7-sulfonamide 1,1-Dioxide (mixture of isomers)
    • 6-Chloro-3-(5-norbornen-2-yl)-7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-1,1-dioxide
    • Anhydron
    • Aquirel
    • Doburil
    • Fluidil
    • Lilly 35483
    • MDi 193
    • Renazide
    • Valmiran
    • HMS3411D03
    • 6-Chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
    • CYCLOTHIAZIDE [USAN]
    • HMS2236K04
    • 3-{bicyclo[2.2.1]hept-5-en-2-yl}-6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
    • HSDB 3310
    • NINDS_000904
    • C03AA09
    • 2259-96-3
    • 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
    • s6611
    • Cyclothiazidum [INN-Latin]
    • Lilly 35,483
    • CYCLOTHIAZIDE [WHO-DD]
    • CYCLOTHIAZIDE [HSDB]
    • 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide
    • SDCCGSBI-0050309.P004
    • NCGC00024745-03
    • BRD-A38675539-001-01-0
    • NCGC00022985-02
    • CYCLOTHIAZIDE [USP-RS]
    • SR-01000075796-3
    • HMS2093A19
    • 6-Chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
    • 3-Bicyclo[2.2.1]hept-5-en-2-yl-7-chloro-1,1-dioxo-1,2,3,4-tetrahydro-1lambda*6*-benzo[1,2,4]thiadiazine-6-sulfonic acid amide
    • LP00321
    • SR-01000075796-4
    • Ciclotiazida [INN-Spanish]
    • CAS-2259-96-3
    • 3-Bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
    • 3-(bicyclo(2.2.1)hept-5-en-2-yl)-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
    • 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
    • 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-, 1,1-dioxide
    • J-014778
    • Spectrum5_001639
    • DB00606
    • Tox21_110124_1
    • C3392
    • 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-,1,1-dioxide
    • EINECS 218-859-7
    • DTXSID3022871
    • HMS3266L17
    • AB00053281_04
    • P71U09G5BW
    • CYCLOTHIAZIDE [JAN]
    • NCGC00015288-14
    • NCGC00015288-09
    • SBI-0050309.P003
    • Anhydron (TN)
    • 6-CHLORO-3,4-DIHYDRO-3-(2-NORBORNEN-5-YL)-2H-1,2,4-BENZ OTHIADIAZINE-7-SULFONAMIDE 1,1-DIOXIDE
    • Biomol-NT_000224
    • EN300-18472036
    • 3-Bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide #
    • GTPL4167
    • CS-0020935
    • C 9847
    • KBioGR_000519
    • CYCLOTHIAZIDE [ORANGE BOOK]
    • CCG-204416
    • D01256
    • AKOS024458615
    • Lopac0_000321
    • 3-(2-bicyclo[2.2.1]hept-5-enyl)-6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
    • NCGC00015288-05
    • Cyclothiazide [USAN:USP:INN:BAN]
    • BRD-A38675539-001-05-1
    • HMS3675D03
    • Lilly 35483; MDi 193; Renazide; Valmiran
    • EU-0100321
    • 3-Bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-1,1-dioxo-1,2,3,4-tetrahydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide(Clothiazide)
    • NCGC00015288-04
    • Pharmakon1600-01503263
    • BDBM50192229
    • Tox21_110124
    • D81850
    • BPBio1_001320
    • NSC-758431
    • NCGC00024745-02
    • NCGC00024745-04
    • SCHEMBL121096
    • 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-sulfonamide 1,1-dioxide
    • 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide
    • DTXCID302871
    • Cyclothiazide (JAN/USAN/INN)
    • AS-76539
    • HY-101165
    • HB0221
    • SR-01000075796-1
    • NCGC00261006-01
    • SR-01000075796
    • HMS502N06
    • NS00027226
    • Ciclotiazida
    • Q5199066
    • CYCLOTHIAZIDE [INN]
    • NSC 758431
    • Ciclotiazide
    • CYCLOTHIAZIDE (MART.)
    • Ciclotiazida (INN-Spanish)
    • Cyclothiazide (USAN:USP:INN:BAN)
    • NCGC00015288-06
    • 6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiazidiazine-7-sulfonamide-1,1-dioxide
    • IDI1_000904
    • KBio1_000904
    • SMR000653479
    • Disodiumhexafluorozirconate
    • FT-0665417
    • 3-{bicyclo[2.2.1]hept-5-en-2-yl}-6-chloro-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide
    • 3-Bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-1,1-dioxo-1,2,3,4-tetrahydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide
    • 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide
    • CYCLOTHIAZIDE [VANDF]
    • 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2-4-benzothiadiazine-7-sulfonamide1,1-dioxide
    • Cyclothiazidum
    • DivK1c_000904
    • MLS001077326
    • BRN 0722843
    • CYCLOTHIAZIDE [MI]
    • 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-, 1,1-dioxide
    • C14H16ClN3O4S2
    • CYCLOTHIAZIDE (USP-RS)
    • Ciclotiazide [DCIT]
    • Cyclothiazidum (INN-Latin)
    • UNII-P71U09G5BW
    • Spectrum4_000050
    • CHEMBL61593
    • 6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiazidiazine-7-sulfonamide-1 ,1-dioxide
    • 3-BICYCLO
    • CYCLOTHIAZIDE [MART.]
    • Tox21_500321
    • NCGC00015288-07
    • 6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
    • CHEBI:31448
    • 3-Bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
    • NSC758431
    • HMS3373E04
    • HMS3261A03
    • BRD-A38675539-001-12-7
    • BRD-A38675539-001-11-9
    • DA-62599
    • BRD-A38675539-001-10-1
    • MDL： MFCD00210192
    • Inchi： 1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)
    • InChI Key： BOCUKUHCLICSIY-UHFFFAOYSA-N
    • SMILES： ClC1C(=CC2=C(C=1)NC(C1CC3C=CC1C3)NS2(=O)=O)S(N)(=O)=O

Computed Properties

  • Exact Mass: 389.02700
  • Monoisotopic Mass: 389.027075
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 3
  • Hydrogen Bond Acceptor Count: 7
  • Heavy Atom Count: 24
  • Rotatable Bond Count: 2
  • Complexity: 758
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 4
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Surface Charge: 0
  • Tautomer Count: nothing
  • XLogP3: nothing
  • Topological Polar Surface Area: 135

Experimental Properties

  • Color/Form: Not determined
  • Density: 1.572±0.06 g/cm3 (20 oC 760 Torr),
  • Melting Point: 234°C(lit.)
  • Boiling Point: 627.3±65.0 °C at 760 mmHg
  • Flash Point: 333.2±34.3 °C
  • Refractive Index: 1.6100 (estimate)
  • Solubility: Almost insoluble (0.012 g/l) (25 o C),
  • PSA: 135.12000
  • LogP: 4.55820
  • Solubility: Not determined
  • Merck: 2754
  • λmax: 273(lit.)
  • Vapor Pressure: 0.0±1.8 mmHg at 25°C

Cyclothiazide Security Information

Cyclothiazide Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
Fluorochem
M01473-10mg
Cyclothiazide
 2259-96-3 >98%
10mg
 ￡70.00 2022-02-28
Fluorochem
M01473-50mg
Cyclothiazide
 2259-96-3 >98%
50mg
 ￡226.00 2022-02-28
S e l l e c k ZHONG GUO
S6611-5mg
Cyclothiazide
 2259-96-3 99.28%
5mg
 ￥795.14 2023-09-15
S e l l e c k ZHONG GUO
S6611-25mg
Cyclothiazide
 2259-96-3 99.28%
25mg
 ￥2432.53 2023-09-15
TRC
C988960-50mg
Cyclothiazide
 2259-96-3
50mg
 $ 190.00 2023-09-08
TRC
C988960-100mg
Cyclothiazide
 2259-96-3
100mg
 $ 227.00 2023-09-08
TRC
C988960-250mg
Cyclothiazide
 2259-96-3
250mg
 $ 448.00 2023-09-08
TRC
C988960-1g
Cyclothiazide
 2259-96-3
1g
 $1629.00 2023-05-18
SHANG HAI XIAN DING Biotechnology Co., Ltd.
C3392-100mg
Cyclothiazide (mixture of isomers)
 2259-96-3 95.0%(LC)
100mg
 ￥1590.0 2022-06-09
SHANG HAI XIAN DING Biotechnology Co., Ltd.
C3392-25mg
Cyclothiazide (mixture of isomers)
 2259-96-3 95.0%(LC)
25mg
 ￥590.0 2022-06-09

Cyclothiazide Production Method

Cyclothiazide Suppliers

Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:2259-96-3)Cyclothiazide
Order Number:A1199752
Stock Status:in Stock
Quantity:100mg
Purity:99%
Pricing Information Last Updated:Friday, 30 August 2024 02:40
Price ($):172.0

Cyclothiazide Related Literature

Related Categories

Additional information on Cyclothiazide

Cyclothiazide (CAS No. 2259-96-3): A Comprehensive Overview of Its Properties and Applications

Cyclothiazide (CAS No. 2259-96-3) is a thiazide-like diuretic with a unique pharmacological profile. This compound has garnered significant attention in both research and clinical settings due to its distinct mechanism of action and therapeutic potential. As a sulfonamide derivative, Cyclothiazide exhibits properties that differentiate it from conventional thiazide diuretics, making it a subject of ongoing scientific investigation.

The chemical structure of Cyclothiazide features a benzothiadiazine core, which contributes to its specific biological activity. Researchers have noted its ability to modulate ion channels in renal tissues, leading to its classification as a chloride channel inhibitor. This mechanism underlies its primary effects on fluid balance and electrolyte regulation in physiological systems.

Recent studies have explored the potential of Cyclothiazide beyond its traditional applications. The compound has shown promise in neurological research, particularly in studies investigating synaptic transmission and neuroprotection. These emerging applications have sparked renewed interest in Cyclothiazide pharmacology among neuroscientists and pharmacologists.

From a pharmaceutical perspective, Cyclothiazide demonstrates favorable pharmacokinetic properties. Its oral bioavailability and tissue distribution characteristics make it suitable for various research applications. The compound's metabolic stability and clearance profile have been extensively studied, providing valuable data for researchers working with this molecule.

In the context of current medical research trends, Cyclothiazide has been investigated for potential applications in metabolic disorders. Some preclinical studies suggest it may influence glucose metabolism and insulin sensitivity, though these findings require further validation in clinical settings. This aligns with growing scientific interest in repurposing existing drugs for new therapeutic indications.

The synthesis of Cyclothiazide involves specialized organic chemistry techniques, with particular attention to the formation of its characteristic heterocyclic structure. Analytical methods for Cyclothiazide characterization typically employ high-performance liquid chromatography (HPLC) and mass spectrometry techniques to ensure purity and proper identification.

From a commercial perspective, Cyclothiazide remains an important compound for pharmaceutical research and drug development applications. Its unique properties continue to make it valuable for studying renal physiology and ion transport mechanisms. The global market for research-grade Cyclothiazide has shown steady growth, reflecting its ongoing relevance in scientific investigations.

Safety considerations for handling Cyclothiazide in laboratory settings emphasize standard chemical safety protocols. While not classified as highly hazardous, proper personal protective equipment and ventilation measures are recommended when working with this compound. Researchers should consult material safety data sheets for specific handling guidelines.

Recent advancements in molecular pharmacology have shed new light on Cyclothiazide's mechanism of action at the atomic level. Structural biology studies using X-ray crystallography and computational modeling have provided insights into how the compound interacts with its molecular targets. These findings may inform the design of next-generation diuretics with improved specificity.

The stability profile of Cyclothiazide under various storage conditions has been well-documented. For optimal preservation, the compound should be stored in controlled environments with protection from moisture and light exposure. These storage recommendations help maintain the compound's chemical integrity for research purposes.

In the context of comparative pharmacology, Cyclothiazide exhibits distinct advantages over some conventional diuretics in specific experimental paradigms. Its pharmacodynamic profile makes it particularly useful for studies requiring precise modulation of renal function without excessive electrolyte disturbances.

Emerging research areas involving Cyclothiazide include investigations into its potential effects on cellular signaling pathways beyond its classical diuretic action. Some studies suggest possible interactions with intracellular second messenger systems, opening new avenues for understanding its broader pharmacological effects.

The formulation of Cyclothiazide for research purposes typically involves preparation as a high-purity powder or standardized reference material. Quality control measures ensure batch-to-batch consistency, which is crucial for reproducible experimental results in pharmacological studies and mechanistic research.

From a regulatory standpoint, Cyclothiazide is recognized as an important research chemical with established safety profiles for laboratory use. Researchers working with the compound should be aware of local regulations regarding chemical handling and disposal procedures to ensure compliance with environmental and safety standards.

The future research directions for Cyclothiazide may include more detailed investigations into its molecular targets and potential applications in precision medicine approaches. As our understanding of renal pathophysiology advances, Cyclothiazide may serve as a valuable tool compound for developing targeted therapeutic strategies.

2259-96-3 (Cyclothiazide) Related Products

Recommended suppliers
Amadis Chemical Company Limited
(CAS:2259-96-3)Cyclothiazide
A1199752
Purity:99%
Quantity:100mg
Price ($):172.0
Email